Do you want to read an article? Please log in or register.
Pro-inflammatory Effects of Hypoglycemia in Humans with or without Diabetes.
Diabetes - GeneralType 1 DiabetesGlycemic Control
Related content
Diabetes - General
Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial
Lancet Diabetes Endocrinol.
Sabatine MS, Leiter LA, Wiviott SD, Giugliano RP, Deedwania P, De Ferrari GM, Murphy SA, Kuder JF, Gouni-Berthold I, Lewis BS, Handelsman Y, Pineda AL, Honarpour N, Keech AC, Sever PS, Pedersen TR
doi: 10.1016/
Diabetes - GeneralType 2 DiabetesGlycemic Control
Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial
JAMA.
Wysham C, Bhargava A, Chaykin L, de la Rosa R, Handelsman Y, Troelsen LN, Kvist K, Norwood P
doi: 10.1001/jama.2017.7117.
Type 2 Diabetes
The effects of dapagliflozin on cardio-renal risk factors in patients with type 2 diabetes with or without renin-angiotensin inhibitor treatment: a post hoc analysis
Diabetes Obes Metab.
Scholtes RA, van Raalte DH, Correa-Rotter R, Toto RD, Heerspink HJL, Cain V, Sjöström CD, Sartipy P, Stefánsson BV
doi: 10.1111/dom.13923.
Diabetes - GeneralType 1 DiabetesGlycemic Control
Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes: The SWITCH 1 Randomized Clinical Trial
JAMA.
Lane W, Bailey TS, Gerety G, Gumprecht J, Philis-Tsimikas A, Hansen CT, Nielsen TSS, Warren M, Group Information; SWITCH
doi: 10.1001/jama.2017.7115.
COMMENTED
Diabetes - General
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial
Lancet Diabetes Endocrinol.
Ray KK, Colhoun HM, Szarek M, Baccara-Dinet M, Bhatt DL, Bittner VA, Budaj AJ, Diaz R, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Loizeau V, Lopes RD, Moryusef A, Murin J, Pordy R, Ristic AD, Roe MT, Tuñón J, White HD, Zeiher AM, Schwartz GG, Steg PG, ODYSSEY OUTCOMES Committees and Investigators.
doi: 10.1016/S2213-8587(19)30158-5.
COMMENTED
Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes
★ 1
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
★ 3
Recommended and commented by
Prof. Dr Isabella Sudano, Faculty Member
doi: 10.1001/jama.2020.1906.
Type 2 Diabetes
Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial
Lancet Diabetes Endocrinol
Jongs N, Greene T, Chertow GM, McMurray JJV, Langkilde AM, Correa-Rotter R, Rossing P, Sjöström CD, Stefansson BV, Toto RD, Wheeler DC, Heerspink HJL, DAPA-CKD Trial Committees and Investigators.
doi: 10.1016/S2213-8587(21)00243-6
Type 2 Diabetes
Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial
Lancet Diabetes Endocrinol
Heerspink HJL, Jongs N, Chertow GM, Langkilde AM, McMurray JJV, Correa-Rotter R, Rossing P, Sjöström CD, Stefansson BV, Toto RD, Wheeler DC, Greene T, DAPA-CKD Trial Committees and Investigators.
doi: 10.1016/S2213-8587(21)00242-4
Type 2 Diabetes
Effects of a whey protein pre-meal on bone turnover in participants with and without type 2 diabetes - a post hoc analysis of a randomized, controlled, crossover trial
Diabet Med
Bjørnshave A, Lykkeboe S, Hartmann B, Holst JJ, Hermansen K, Starup-Linde J
doi: 10.1111/dme.14471